Engineer position in Bioinformatics and Systems Immunology
CDD-OD · IE · 12 mois (renouvelable) Bac+5 / Master Curie Institute · Paris (France)
Date de prise de poste : 1 juin 2022
Cancer biology single-cell RNAseq Spatial transcriptomic
Institut Curie (http://www.institut-curie.org) is one of the biggest European institutions for cancer research with a strong interdisciplinary tradition. It is located in the center of Paris in France, in a both cultural and scientific rich environment. This is a joint position open between the team of tumor immunobiology of Dr Emanuela Romano at the Inserm Unit 932 (https://science.institut-curie.org/research/integrated-biology/u932-immunity-and-cancer/) and the "Stress and Cancer" Laboratory at the Inserm U830 headed by Drs Mechta-Grigoriou (U830 - Cancer, Hétérogénéité, Instabilité et Plasticité (CHIP) - Centre de recherche de l'Institut Curie). Our department includes over 20 independent research teams in the fields of basic and applied immunology and cancer biology, working in a very collaborative and international environment. The selected candidate will work in close collaboration with biologists and bio-informaticians under the supervision of Drs Mechta-Grigoriou and Emanuela Romano. The open position is in line with recent developments at the interface between Immunology and Bioinformatics.
The successful candidate will be involved in an immunology project in close collaboration with bioinformaticians and medical staff with the aim of better understanding cell networks associated to immunotherapy outcome in breast and ovarian cancers. Treatments in combination with anti-PD-(L)1 antibodies have significantly increased the response rates for several patients with solid tumors. Despite these advances, the contribution of distinct tumor microenvironments to immunotherapy response remains largely unknown. Myeloid cells and cancer-associated fibroblasts (CAFs) are major players in immune evasion. We hypothesize that by tracing the adaptation of TNBC to chemo-immune checkpoint blockade through deep characterization of the tumor, immune, and stromal microenvironment (TISME) using human samples, obtained prior and on-treatment in the course of academic clinical trials, we will address this clinical need. More specifically the successful candidate will apply innovative bioinformatics pipelines, to reach a high resolution, but also global level understanding of TISME networks.
We expect a candidate with a Master or PhD degree (depending on candidate). Ideal candidate will have a background in Bioinformatics, Biology, Biostatistics or applied mathematics. Good knowledge in approaches for high- throughput data analysis especially single cell analysis, and multivariate statistics is required. Some knowledge of cell biology and/or immunology is not mandatory but would be appreciated.
Candidate will analyse NGS data, 10X genomics single Cell RNAseq and spatial transcriptomics data using dedicated pipelines as Seurat. Candidate is expected to individually study the bibliography and be aware of the last developments in the domain of interest. Candidate should be apt to team work, be autonomous, enthusiastic, have initiative and good communication skills.
- Experience in management and manipulation of omic and high throughput data
- Knowledge in statistics
- Experience in use of bioinformatics and biostatistics tools for single cell RNAseq analysis
- Experience in computational data analysis and modeling biology
- Programming skills (R, Python and/or bash)
- Specific tools for single Genomics: Seurat, trajectory analysis, clustering approach, integration of data.
- Experience in machine learning methods for the analysis of biological data will be an additive value
The position is open and funded for 1 year with possible extension. Please send your CV, letter of motivation and 2 letters of reference to Drs Mechta-Grigoriou (email@example.com), Emanuela Romano (firstname.lastname@example.org), Yann Kieffer (email@example.com) and Christel Goudot (Christel.Goudot@curie.fr).
Date limite : None
Offre publiée le 9 mars 2022, affichage jusqu'au 6 juin 2022